hVIVO PLC chief executive Yamin ‘Mo’ Khan talked with Proactive's Stephen Gunnion about the company’s newly inked £2 million contract with a biotech client. The deal will fund the final stage of hVIVO’s human metapneumovirus (hMPV) characterisation study, paving the way for future human challenge trials. Khan explained that hVIVO had already completed a successful pilot study involving a small group of volunteers. The new study will expand the trial to a larger population to confirm infection levels and establish a robust challenge model for hMPV research. “This, hopefully, if successful, will go a long way in accelerating the development of an hMPV vaccine,” Khan stated. He emphasised that there are currently no approved vaccines or treatments for hMPV, which has been gaining media attention due to its increasing prevalence in children. The study, which was not included in hVIVO’s year-end sales pipeline, came as a new business opportunity in early 2025. hVIVO expects to complete the characterisation study by June, with commercial human challenge trials potentially beginning in the second half of the year. Stay tuned for more updates on hVIVO’s research progress. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and enable notifications for more exclusive interviews. #hVIVO #Biotech #hMPV #ClinicalTrials #VaccineResearch #MedicalInnovation #Healthcare #Investing #Pharmaceuticals #ProactiveInvestors